Omada Health's (OMDA) Sell (D) Rating Reaffirmed at Weiss Ratings

Key Points

• Omada Health's stock has been reaffirmed with a "sell (d)" rating by Weiss Ratings, indicating concerns about the company's performance.
• Research analysts have mixed views on Omada Health, with seven analysts rating it as a Buy, while two hold and one rates it as a Sell, reflecting diverse expectations in the market.
• The company recently reported a revenue of $61.37 million for the quarter, exceeding expectations, but its earnings per share missed estimates by 7 cents.

Omada Health (NASDAQ:OMDA - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also issued reports on OMDA. Canaccord Genuity Group raised their price target on shares of Omada Health from $27.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. The Goldman Sachs Group initiated coverage on shares of Omada Health in a research note on Tuesday, July 1st. They set a "buy" rating and a $29.00 price target for the company. Barclays raised their price target on shares of Omada Health from $21.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Baird R W upgraded shares of Omada Health to a "hold" rating in a research note on Friday, September 5th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Omada Health in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $19.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Omada Health has an average rating of "Moderate Buy" and an average target price of $25.00.

Omada Health Stock Up 2.9%

Shares of OMDA stock opened at $23.98 on Wednesday. The business's 50 day moving average is $21.78. Omada Health has a 12-month low of $14.14 and a 12-month high of $28.40.

Omada Health (NASDAQ:OMDA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The firm had revenue of $61.37 million for the quarter, compared to the consensus estimate of $55.17 million. Omada Health has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Omada Health in the 2nd quarter valued at $32,000. Ilex Capital Partners UK LLP bought a new position in Omada Health in the 2nd quarter valued at $201,000. Sandia Investment Management LP bought a new position in Omada Health in the 2nd quarter valued at $366,000. XTX Topco Ltd bought a new position in Omada Health in the 2nd quarter valued at $414,000. Finally, Walleye Capital LLC bought a new position in Omada Health in the 2nd quarter valued at $458,000.

Omada Health Company Profile

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.